NTRK1 and cancer: The targeted therapies include those directed towards EGFR, anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), proto-oncogene, receptor tyrosine kinase (MET), RET proto-oncogene (RET), Kirsten rat sarcoma virus (KRAS), and programmed death-ligand 1 (PD-L1), and they work by disrupting the signaling pathways that are responsible for cancer cell growth [22].